Physician profile
Mayer Gorbaty
NPI 1710083241
$13,249.96
in general payments reported to CMS, 2019-2025
39 companies · $72.40 in 2025
The $72.40 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,838 · 2020: $6,055 · 2021: $56.20 · 2022: $224 · 2023: $2,808 · 2024: $197 · 2025: $72.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,275 · Food and Beverage: $486 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,275.00 |
| Food and Beverage | $485.93 |
| Education | $316.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $3,920.78 | 2020 | |
| Beigene USA, INC. | $2,275.00 | 2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $1,893.59 | 2019-2020 | |
| Janssen Biotech, INC. | $1,295.38 | 2019-2024 | Rybrevant |
| Beigene, Ltd. | $450.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $374.63 | 2019-2022 | |
| Pfizer INC. | $344.33 | 2019-2024 | |
| Lilly USA, LLC | $324.88 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $224.69 | 2019-2025 | |
| Genentech USA, INC. | $217.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $213.24 | 2019-2024 | Augtyro, Opdivo |
| Genzyme Corporation | $197.87 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $187.40 | 2019-2023 | Iclusig |
| Merck Sharp & Dohme LLC | $146.68 | 2019-2020 | |
| Exelixis INC. | $121.42 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $87.03 | 2019-2022 | |
| Incyte Corporation | $77.16 | 2019-2025 | Niktimvo, Jakafi |
| Celgene Corporation | $76.62 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $75.73 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $75.55 | 2020-2023 | Provenge |
| Janssen Pharmaceuticals, INC | $68.68 | 2019-2020 | |
| Gilead Sciences, INC. | $67.86 | 2019-2022 | |
| Seagen INC. | $60.88 | 2019-2020 | |
| Amgen INC. | $53.27 | 2019-2020 | |
| Puma Biotechnology, INC. | $46.64 | 2023-2025 | |
| Daiichi Sankyo INC. | $44.11 | 2020-2022 | |
| Eisai INC. | $37.86 | 2019 | |
| Tesaro, INC. | $36.30 | 2019 | |
| Portola Pharmaceuticals, LLC | $34.89 | 2020 | |
| Taiho Oncology, INC. | $33.44 | 2019 | |
| Jazz Pharmaceuticals INC. | $32.59 | 2023 | Zepzelca |
| Rigel Pharmaceuticals, INC. | $31.08 | 2024 | Rezlidhia, Tavalisse |
| Karyopharm Therapeutics INC. | $29.08 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.33 | 2019 | |
| Amag Pharmaceuticals, INC. | $19.87 | 2020 | |
| Abbvie INC. | $16.98 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.22 | 2020 | |
| Verastem, INC. | $12.14 | 2019 | |
| Emd Serono, INC. | $10.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayer Gorbaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.